yissum ações integradas nacionais e internacionais · 2015-06-01 · 06/10/2014, 12:34 gali...

0

Yissum

Ações Integradas Nacionais

e Internacionais

Renée Ben-Israel, Vice Presidente,

Propriedade Intelectual

Yissum, Research Development Company of

The Hebrew University of Jerusalem, Ltd

Curitiba, Paraná, Brasil - 19-22 Maio 2015

FORTEC – 2015

1

Roteiro

Introdução

A Universidade Hebraica de Jerusalém

Yissum

Conclusões

Modelos – 3 modelos de comercialisação

Israel

2

3

Eco-sistema de suporte

Israel: data

Area - Total 120,770 / 22,072 km2 (151st)8,019 / 8,522 sq mi - Water (%)~2% (1)

Population - 8,296,000 (2013 estimate) (1)

Density365,3/km2 (30th), 946.1/sq mi (1)

GDP (PPP)2013 estimate - Total $32,140 PPP dollars

Gross domestic product : 290.6 billion USD (2013) (1)

Education expenditures – 5.9% of GPD (1)

Gross domestic expenditure on R&D – 4,9% (2009) (2) (3)

Sources: (1)Wikipedia, (2)OECD (3) OECD average:2.3%

Alguns sucessos

Waze – the smart phone social GPS

“disk on key” – USB flash drive

Given Imaging – capsule endoscopy

Ituran - location & control of vehicles

Check Point - security systems

Netafim – drip irrigation systems

The cherry tomatoes

5

6

Israel’s Top University

HUJI

No. 1 in Israel

No. 5 in Asia-Pacific region

No. 59 worldwide

No. 27 worldwide in Computer Science

No. 38 worldwide in Natural Sciences &

Mathematics

* U of Texas Institute of Higher Education, Shanghai Jiaotong University 2013

Scale of Academic Excellence

Bar-Ilan

Univ.

Ben-Gurion

Univ.

Technion

Tel Aviv

Univ.

The Hebrew University

of Jerusalem

53

100-150

301-400

Weizmann

Inst.

93

78

O fenomeno

Dan Senor, Saul Singer, 2011

8

Yissum

Fundada em 1964

26 experts nas areas de:

Desenvolvimento de Negócios

Pesquisa Colaborativa

Patentes

Legal (contratos)

Admin e finanças

Chefiada por: Yaacov Michlin

Yissum - Estrutura Organizacional

Adv. Bob Trachtenberg

General Counsel

Yaacov Michlin, CEO

Intellectual

Propery (4)

Finance (5) Business

Development (11)Legal (3)

Adv. Martha Fredman

Deputy General Counsel

Renee Ben Israel

VP, IP

Tamar Gallily

Patent Attorney

Dr. Michal Levy

VP, Head of Business Development,

Agritech & Environment

Dr. Shoshi Keynan

VP, Head of Business Development,

Healthcare

Ariela Markel

VP Business Development, Healthcare

Tamir Huberman

VP Business Development Computer

Science & Director of IT

Dr. Dov Reichman, VP Business

Development – Chemistry & Physics

Irina Abramzon, Business Development

Agri-Tech & Veterinary

Sharon Cohen

CFO

Avi Katz

Controller

Dr. Itzik Goldwaser

VP, Head of Research Collaborations

Business

Intelligence

Gustavo Fuchs

Business and IP

Intelligence Officer

Dana Gavish Fridman

Director of Marketing

Marketing

10

Onde a Ciência Significa Negócios – estrutura legal

Business leaders

Business-oriented

organization

Non-profit organization

11

Yissum – modelos de negócios

Pesquisa

Colaborativa

Empresa de

Spin Off

Pesquisadores

Laboratório

de Recursos

Tecnologias

Disponíveis

Contrato de

Licença

Yissum – modelos de negócios

Licenciamento a companhias

existentes

Colaborações com indústria

Pesquisa mantida nos

laboratórios universitários

Criação de novas companhias

Criação de companhia incubada

Income Distribution

40%

20%

40%

Royalty Distribution

Researcher

Researcher's Laboratory

Yissum & Huji

66,6%

33.3%

Incubator Founder's Equity Distribution

Researcher

Yissum

50,0%50.0%

Start-Up Founder's Equity Distribution

Researcher

Yissum

16

51 anos de Transferência de Tecnologias

8,537 patents

2,403

inventions

705 licenses

88 spin-offs

Produtos baseados em tecnologias da Universidade Hebraica e

comercializados pela Yissum geram > $2B anuais em vendas

17

Propriedade Intelectual

2013 Snapshot170 new inventions

47 new patents granted

Intellectual Property at HUYissum owns all IP

developed at HU

Researchers receive

40-60% of revenues

Life Science & Biotechnology

54%

Materials &

Chemistry

24%

Agriculture,

Food &

Nutrition 9%

Micro & Opto Electronics

5%

Computer Science &

Engeneering10%

A variety

of new

inventions

Humanities 2%

Yissum’s Biotech Product Pipeline:

Vekacia ® (Novagali)

Cyclokat ® (Novagali)

Ladostigil, (Avraham)

BC819 (Biocancell)

Anti Angiogenic (Tiltan)

MRX4 (Morria)

Acc. Levodopa (Intec)

LABR-312 ( Biorest)

CatioProst ® (Novagali)

Apocell (Enlivex)

CCS/C (Nasvax)

EPOdure (Medgenics)

AB103 (Atox Bio)

Cortiject ® (Novagali)

Phase I Phase II Phase III

MRX6 (Morria)

Acc. Zalepon (Intec)

Acc. Baclofen (Intec)

PRX105 (Protalix)

BL7040 (Bioline Rx)

Protexia (Pharmathene)

MM-002 (Moebius)

6

2

2010

159

Israel*Yissum

Phase III

Phase II

Phase I

*Source: ILSI Database - 2010

Promitil (Lipomedix)

19

88 Spin-Offs desde 1964

20

Alcance Global

27

$16M - Acordos de Colaboração – longo

prazo

7 ongoing projects

9 research projects

10 research projects

2 research projects

1 research project

2 research projects

4 ongoing projects

1 research project

Lockheed Martin and Yissum sign R&D collaboration

06/10/2014, 12:34Gali WeinrebThe Hebrew University collaboration includes quantum and material sciences.Lockheed Martin Israel Ltd. and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, have signed an agreement to conduct joint collaborative research. The collaboration will focus on basic and applicable scientific research in areas such as quantum information sciences and material sciences, and other areas

29

Yissum cria de 8-10

novas companhias e

licencia ~60 tecnologias

anualmente

Centenas de novos

empregos são criados

para a força de trabalho

capacitada

$16 M são gerados do

trabalho de pesquisa

colaborativa com a

indústria

Benefícios adicionais

Iniciativas comerciais:

Além do Vale da Morte

Academic

Projects/

Grants

Baby Seed Kamin/

Nofar

Magneton,

Incubators

Independent

Companies

Extensive Long Term

Collaboration

102 projects

approved for

Yissum’s

internal

program

Such as

Roche,

Google, etc

Funding through the

Office of the Chief

Scientist

The Financial Valley of

Death

30

Integra

Holdings/ Ag-

Bio Fund

HUJI Projects

+ New!

Collaboration

with Shaare

Zedek Hospital

32

Modelo I –Ações integradas: NovagaliIncubadora Europea

Gustavo Fuchs – Business & IP Intelligence Officer

Um jovem pesquisador

1990

Dr. Simon Benita, pesquisador na area de nano-delivery em drogas de CNS (Central Nervous System) contra Alzheimer

Notou que o mesmo sistema poderia ser adequadono de transmissão de medicamentos do sistemaocular

33

34

Ophthalmology Market: The Need

Growing market Numerous unmet needs Increasing number of new molecules

But

Current formulation limitations:

Poor Tolerability Low Bioavailability Many hurdles for lipophilic drugs Inability to reach the back of the

eye to treat retinal diseases

The need for an Ophthalmic DD Expert

Prof. Simon BenitaUniversity of JerusalemExpert in Drug Delivery

Prof. Marco Fabrizio SaettoneUniversity of PisaExpert in Ophthalmic DD

1992 – Proof of Principle

36

1996 - First Patent Filed (Granted 1999)

37

First offer to establish an Incubator

Company

An Israeli investor proposes to invest

$300k to start an incubator to develop

the technology

Conversations with a Biotech Science Park based near Paris – a better proposal

38

The next international collaboration

1997 – Incubator Project

66 biotech companies

20 academic research labs

17 shared-access technology platforms and technical facilities

86,538 m2 of real estate

€272,25 million in equity funding raised by Genopole®

companies

942 patents filed by campus companies

26 molecules or biotherapies in development or on the market,

from the regulatory preclinical phase through to market

launch

2 186 direct jobs

2000 – Novagali was funded

by Prof. Benita and Yissum

2000 - Licensing Agreement

2000 – 2004 - First Investments

2000 - 3.78 M€

2003 - 5 M€

2004 - 9 M€

41

• To strengthen the valuable assets of the company• To conduct Phase I/II clinical trials• To invest in laboratory, pilot and production

equipment.

2001 - Second Patent Filed (Granted 2003)

42

Novagali today

43

Novagali Pharma Company today cont.

~ 45 employees including 13 doctors of science, medicine or pharmacy

Located in Evry (Paris suburb – Genopôle)

5 rounds of financing for a total amount of € 81m

Listed in Euronext in 2010 and acquired by Santen Japan in Dec. 2011

Formulation Analytical & QC Scale Up Pilot Manufacturing

pre-clinical Studies Clinical Development Regulatory Commercialization

44

Products in the Pipeline

45

46

Renée Ben-Israel, VP Intellectual Property

Yissum, Research Development Company of

The Hebrew University of Jerusalem, Ltd

LIGHTING THE WAY WITH CUTTING-EDGE SOLUTIONS

Modelo II

Qlight Nanotech, Ltd

De 2009 a 2015 – a tragetória

Best Nanotechnology Company Of The Year" Award Given To Qlight

Nanotech At The NanoIsrael 2014 Conference (Yahoo, HUJI)

47

Nosso herói:

48

Prof Uri Banin

the Institute of Chemistry and

the Center for Nanoscience and

Nanotechnology,

The Hebrew University of

Jerusalem,

Givat Ram, Jerusalem, 91904,

Israel

Com participações internacionais

49

Laboratório Prof Banin – áreas de

estudo

Nanoscience and Nanotechnology:

Basic Science and Applications of Nanoparticles Synthesis and characterization of novel semiconductor nanocrystals

and nanostructures and their assemblies

Size dependent optical and electronic properties of nanocrystals

Single nanostructure microscopy and spectroscopy

Alternative energy solutions using nanoparticles

Lasers and optical devices based on colloidal semiconductor

nanostructures

Biological, medical and sensing applications of nanocrystals

Non linear optical properties of semiconductor nanocrystals and

nanorods

Electrical Transport studies on single nanorods and nanocrystal

arrays

50

Prof Banin e Qlight Nanotech

Pesquisador regular na universidade

Em busca de soluções a problemas da

arte existente

Quando apresentou o projeto de pesquisa,

era considerado um tanto futurístico

em 2009, depois de ter colaborado com

outras companhias de nanotecnologia,

Banin decide iniciar sua própria

companhia => Yissum

51

Modelo de negócio:

Uma start-up utilisando somas

governamentais (Israel OCS - Office of

Chief Scientist) por um lado, e por outro

uma colaboração estratégica com uma

companhia (Merck KGaA), baseada em

suas invenções na área do uso de

nanocristais em display e aplicações na

área de iluminação

52

Modelo de negócio

A lógica da criação da start-up:

Escolher um modelo de negócio mais

adequado(*) e a aplicação mais “quente” do

mercado.

Qlight/Merck colocaram um foco no mercado

de LCD (liquid crystal display)/iluminação para

substituir a tecnologia existente

Na realidade existe toda uma área (a

plataforma) não desenvolvida pela Merck

(*) Best use of the technology

53

Israel - políticas de apoio, histórico

1968 – criação do cargo de “Cientista Chefe”

do Ministério da Indústria e Comércio com o

mandato de subsidiar projetos de pesquisa

científica conduzidos por companhias (setor

privado)

Objetivo: desenvolver indústrias baseadas

em ciência, com orientação para exportação

para promover a criação de empregos e

ampliar e explorar a infra- estrutura científica

existente e promover os RH de alta qualidade

Israel - políticas de apoio, incentivos

à indústria

Incentivos fiscais à indústria:

Subsídios de até 50% dos custos de

pesquisa em companhias existentes

66% em start-ups

Israel - políticas de apoio

Programas específicos:

Magnet, Nofar, Tnufa – para incentivar pesquisa

conduzida em consórcios em estágios pré-

competitivos

Kamin – para levar projetos inventivos à fase de

prova de conceito

Criação de incubadoras tecnológicas

Programas de colaboração internacional -

bilaterais e multilaterais

OCS – Office of the Chief Scientist – Israel

NOFAR

Israeli government incentives for Industrial

application of Academic Research

Designed to support applied academic research in specific

technological areas (biotechnology, nanotechnology,

medical devices, water & energy storage), in order to

adapt it to relevant applications in the industry, and

promotes the transfer of these technologies to the

industry. Project's budget is up to

USD 130,000 for a period of 12 months. Grants are up to

90% of the approved budget, to be complemented by the

industrial company accompanying the project.

57

Parceria: por que a Merck?

Merck KGaA possue uma posição de

liderança no mercado global de Liquid Crystals

com >60% do mercado. Merck tambem está

investindo significantemente, para se tornar a

maior fornecedora de materiais da próxima

geração de tecnologia de display & lightning a

serem competitivas com outras tecnologias como

por exemplo: OLED (organic LED).

Na realidade a ligação da Universidade com a

Merck existe ainda antes da criação da Qlight

Nanotech.

58

59

Quantum dot semiconductor nanoparticles for energy-efficient

light sources and displays.

The technology improves picture quality in brightness and colour

range.

As origens: uma tecnologia revolucionária

Nova tecnologia

Problemas com tecnologia, arte-prévia

Shells, core shells, multi shells => muita arte-

prévia

Uri Banin estava ciente da situação => procura

novas soluções

De quantum dots a quantum “rods”

Rods possuem caracteristicas superiores em

aplicações relevantes como de direcionamento

(inclusive conseguiu desenvolver “self

assembly”)

61

Estado da arte 2009

62

For example:

A quantum dots technology company, their

business model consisting of:

•Sales of Quantum Dot Concentrate™ material

•Technology licensing of component designs,

like our Quantum Dot Enhancement Film (QDEF)™,

to industrial supply chain partners

Propriedade Intelectual

Patents cover everything from the fundamentals of

quantum dot construction to component and

manufacturing designs. This extensive portfolio is the

result of collaborations between Nanosys and

prestigious universities such as Massachusetts

Institute of Technology (MIT), Lawrence Berkeley

National Labs and Hebrew University, as well as

industry collaborations with companies like Philips-

Lumileds and Life Technologies.

63

Quantum dot

Quantum dot é uma partícula semicondutora

medindo de alguns a dezenas de

nanometros, que é capaz de emitir luz

monocromática de alta qualidade.

64

Quantum rods

Quantum dots convencionais se

parecem com particulas (pontos), mas

os nanocristais produzidos pela

Qliquits/Merck se parecem com rods

(linhas)

Portanto, foram denominados

"quantum rods“.

65

Vantagens

Economia no consumo de energia (o tempo de

uso da bateria do celular é reduzido

consideravelmente)

Produção dos produtos rezultantes a custo muito

reduzido

Em termos de reprodução das cores, quantum

rods podem reproduzir nivel de 100% do leque

das cores em padrões NTSC*.• Produção de côr – sistema americano

( National Television System Committee)

66

Propriedade Intelectual

No início:

Patentes da Yissum sendo exclusivamente

licenciadas a Merck

Com o tempo – patentes conjuntas,

desenvolvidas por inventores de ambas

partes

Patentes de plataforma e patentes de uso

especifico

67

ABEF – Active Brightness Enhancement Film

Qlight está devenvolvendo "ABEF“(*) , uma

pelicula ótica contendo nanomateriais da

Qlight

A pelicula proporciona mais um valor unico: um

aumento significante da claridade em comparação

aos produtos existentes, numa simples estrutura

(*)Active Brightness Enhancement Film

68

69

ABEF: Brightness enhancement technology

for screens and lighting

Qlight’s LCD’s quantum rods

70

The latest samples (May 2014). An LCD using the

left) and Qlight’s LCD)conventional method

71

Capabilidades do Lab do Prof.

Uri Banin do Instituto de Quimica

identificadas

Modelo de negocio: Yissum cria a

start up, Qlight Nano

Investimento por um líder global

Merck KGaA.

Uma bolsa Nofar do governo

israelense (OCS).

Boa cobertura de patentes

O resultado: Uma start up de

successo fundada em 2009, hoje

com laboratórios e escritorios em

Jerusalem, com 24 empregados.

Resumindo:

Congratulations to Qlight!

“Company of The Year 2014” in the Nanotechnology Field

72

Modelo IIIOs maravilhosos tomatinhos (e algunspimento)

74

1948 – Israeli farming takes it’s baby steps.

The Israeli government’s strategic decision:

Investment in Agricultural Research

1973 – Prof. Nachum Keidar and his research

group from the Hebrew University, Faculty of

Agriculture receives government funds

The story of the Israeli Seed Industry

H RabinovitchN Keidar, RIP Y Elkind

75

A revolutionary approach was taken by the Hebrew University’s researchers: taking the ripening inhibiting genes: rin & nor from industrial tomatoes and inserted them into fresh tomatoes using traditional breeding

They created a long shelf life tomato

Till then tomatoes were able to stay fresh for 3-4 days from picking and now – they kept fresh. It could stay for 2-3 weeks!

This changed the tomatoes world’s industry

The story of the Israeli Seed Industry

76

Daniela was born.

The world-famous tomato variety for its tempting

red color and long shelf life.

The story of the Israeli Seed Industry

• Could grow in different

climates around the world.

77

1982 – The big

commercial

success.

The story of the Israeli Seed Industry

Yissum commercialized the new hybrid to Hazera

(Israeli seed company).

78

The story of the Israeli Seed Industry

At the time Hazera was in a bad financial situation and they wanted someone to invest in the company, but no one wanted to do so.

In 1982 – Daniela became a BIG world commercial success. Until then Hazera supplied seeds only for local use. From that point they became a big seed exporter.

79

The global seed industry dramatically

changed by this discovery.

A new world standard for fresh tomatoes was

established.

The breeding group from the Hebrew

University became very popular among the

seed companies.

The story of the Israeli Seed Industry

80

All Israeli seed companies wanted to be part in the celebration.

Yissum, together with Profs. Keidar & Rabinowitch decided to give license to each company on a new variety as they creates them.

The seeds companies from their point of view understood the huge potential in investing in this group and they all started to fund different breeding programs.

All the research is done in the Faculty of Agriculture in the Hebrew University.

The story of the Israeli Seed Industry

81

Yissum signed licensing agreements with multiple

companies.

The agreements include a section ensures that the

breeding and the production will continue to be

done in Israel.

The story of the Israeli Seed Industry

Supporting your local

industry – a strategic

goal.

82

Until today the group developed 1,700 different Hybrid combinations and about 150 are commercialized

Resistance to different diseases.

Growing on one branch.

Cherry tomatoes.

The story of the Israeli Seed Industry

83

In 2006 world giant Vilmorin finalized it’s holdings in Hazera

Genetics, when 40% of the Israeli company’s revenues

relayed on Hebrew University varieties.

Epilogue (part I)

84

Israeli firm Zeraim Gedera was sold to world leader

Syngenta in 2007. In 2010 Syngenta’s revenues from HUJI

varieties topped $40 Million.

Epilogue (part II)

85

In 2010 Israeli company A.B. Seeds was sold to De-Ruiter.

Later on Monsanto’s vegetable Seeds Division.

De-Ruiter was purchased by Monsanto and the Israeli

branch became

Epilogue (part III)

Know the research Group

Phytopathology

Plant Biology

Breeding Projects

Breeding Supporting Technologies

Technology Transfer

Over $50 of BonTom seeds - over 5,000 kg annually

The International Presence

"Breed IT" Comprehensive Information System

renee@yissum.co.il

Obrigada pela atenção!

Visite nosso site

www.yissum.co.il